Patents by Inventor Farah Hedjran

Farah Hedjran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TUMOR-SELECTIVE E1A AND E1B MUTANTS
    Publication number: 20230272349
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Application
    Filed: November 23, 2022
    Publication date: August 31, 2023
    Inventors: Tony REID, Farah HEDJRAN, Shantanu KUMAR
  • Tumor-selective E1A and E1B mutants
    Patent number: 11618888
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 4, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar
  • TUMOR-SELECTIVE E1A AND E1B MUTANTS
    Publication number: 20210171917
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Application
    Filed: November 20, 2020
    Publication date: June 10, 2021
    Inventors: Tony REID, Farah HEDJRAN, Shantanu KUMAR
  • Tumor-selective E1a and E1b mutants
    Patent number: 10876097
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: December 29, 2020
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar
  • TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS
    Publication number: 20190352669
    Abstract: The invention provides, e.g., a recombinant virus comprising (i) a modified TATA box-based promoter, and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter and/or modified CAAT box-based promoter lacks a functional TATA box and/or CAAT box and permit selective expression of the gene in a hyperproliferative cell. The recombinant viruses can be used to treat cell proliferative diseases and disorders, including certain forms of cancer.
    Type: Application
    Filed: January 30, 2018
    Publication date: November 21, 2019
    Inventors: Tony R. Reid, Bryan T. Oronsky, Farah Hedjran, Christopher Larson
  • TUMOR-SELECTIVE E1A AND E1B MUTANTS
    Publication number: 20190136204
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Application
    Filed: August 8, 2018
    Publication date: May 9, 2019
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar
  • Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
    Patent number: 10113151
    Abstract: A composition is provided which comprises a recombinant viral particle comprising a capsid, wherein the viral particle is encapsulated into an anionic liposome comprising lecithin and polyethylene glycol (PEG). A method for preparing and purifying the encapsulated viral particles is provided as well. Methods for treating patients by using the encapsulated viral particles are provided as well.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: October 30, 2018
    Assignee: The Regents of the University of California
    Inventors: Andrew C. Kummel, Sarah L. Blair, Tony R. Reid, William C. Trogler, Farah Hedjran, Natalie Mendez, Vanessa Herrera
  • TUMOR-SELECTIVE E1A AND E1B MUTANTS
    Publication number: 20160017294
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Application
    Filed: May 26, 2015
    Publication date: January 21, 2016
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar
  • COMPOSITION OF VIRAL VECTORS IN LECITHIN LIPOSOMES, PREPARATION METHOD AND TREATMENT METHODS
    Publication number: 20150284691
    Abstract: A composition is provided which comprises a recombinant viral particle comprising a capsid, wherein the viral particle is encapsulated into an anionic liposome comprising lecithin and polyethylene glycol (PEG). A method for preparing and purifying the encapsulated viral particles is provided as well. Methods for treating patients by using the encapsulated viral particles are provided as well.
    Type: Application
    Filed: October 28, 2013
    Publication date: October 8, 2015
    Inventors: Andrew C. Kummel, Sarah L. Blair, Tony R. Reid, William C. Trogler, Farah Hedjran, Natalie Mendez, Vanessa Herrera
  • Tumor selective E1a and E1b mutants
    Patent number: 9073980
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 7, 2015
    Assignee: The Regents of the University of California
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar
  • TUMOR-SELECTIVE E1A AND E1B MUTANTS
    Publication number: 20110318311
    Abstract: Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 29, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Tony Reid, Farah Hedjran, Shantanu Kumar